Skip to main content
. Author manuscript; available in PMC: 2021 Apr 27.
Published in final edited form as: JACC Cardiovasc Interv. 2020 Feb 12;13(8):938–950. doi: 10.1016/j.jcin.2019.11.027

Table 2:

Baseline characteristics of patients according to the type of ACS after TAVR

Unstable angina (n = 208) NSTEMI (n = 5,947) STEMI (n = 586) p value
N 208 5,947 586
Age, yrs 82.7 ± 7.7 80.6 ± 8.8 80.9 ± 9.1 0.003
Male 56.7 55.7 50.5 0.05
White 94.2 91.0 91.8 0.70
Black - 5.3 6.0
Other - 3.7 2.2
Hypertension 94.2 95.0 95.6 0.73
Diabetes mellitus 43.8 51.9 50.7 0.07
Heart failure 83.2 84.1 82.9 0.74
Deficiency anemia 46.6 50.3 51.4 0.50
Alcohol abuse - 1.7 1.9 0.37
Connective tissue disease 5.8 7.8 8.0 0.54
Chronic lung disease 45.2 44.0 41.1 0.37
Coagulopathy 20.2 24.2 23.9 0.41
Depression 21.2 17.8 15.5 0.16
Hypothyroidism 31.3 25.7 28.7 0.07
Liver disease - 3.8 5.1 0.05
Lymphoma - 1.8 2.1 0.24
Electrolyte abnormality 47.6 52.0 52.1 0.46
Obesity 29.8 27.0 25.9 0.56
Paralysis - 4.8 5.6 0.67
Peripheral arterial disease 47.6 46.6 44.2 0.52
Pulmonary hypertension 27.4 25.7 22.0 0.12
Tumor without metastasis 5.8 5.3 5.5 0.96
Weight loss 6.3 9.6 9.2 0.26
Prior bleeding 40.4 41.7 43.3 0.68
Prior stroke 23.6 22.5 22.9 0.92
ESRD - 7.2 6.5 0.10
CKD 31.7 35.0 32.6 0.32
Prior coronary artery disease 93.8 90.6 91.1 0.30
Prior smoking 44.2 38.7 36.5 0.15
Prior revascularization (within 3 yrs before TAVR) 66.8 55.5 47.8 <0.001
Prior ACS (within 1 yr before TAVR) 18.8 22.0 18.4 0.08
Prior PCI (within 6 months before TAVR) 14.9 14.8 15.9 0.77
Prior cardiac device 22.6 17.6 13.3 0.004
Preexisting atrial fibrillation 42.3 40.6 41.0 0.88
Apical TAVR 16.8 13.0 9.6 0.01

Values are mean ± SD or %.

Cells with N <10 were suppressed with (–).

CKD = chronic kidney disease; ESRD = end-stage renal disease on dialysis; NSTEMI = non–ST-segment elevation myocardial infarction; STEMI = ST-segment elevation myocardial infarction; other abbreviations as in Table 1.